Body mass index greater than 35 is associated with severe Clostridium difficile infection

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 1, 2017, Pages 75-81

  Mulki, R ^a   Baumann, A J ^b   Alnabelsi, T ^a   Sandhu, N ^a   Alhamshari, Y ^a   Wheeler, D S ^a   Perloff, S ^a   Katz, P O ^a  

^a EINSTEIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED INFECTION; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HOSPITAL INFECTION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; AGED; CASE CONTROL STUDY; CLOSTRIDIUM INFECTIONS; COHORT ANALYSIS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; HOSPITALIZATION; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; RETROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TERTIARY CARE CENTER; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TERTIARY CARE CENTERS;

EID: 84996946571     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13832     Document Type: Article

References (37)

1. Bartlett JG. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 1994; 18(Suppl. 4): S265–72.
2. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257–62.
3. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372: 825–34.
4. Kuijper EJ, van Dissel JT, Wilcox MH. Clostridium difficile: changing epidemiology and new treatment options. Curr Opin Infect Dis 2007; 20: 376–83.
5. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466–72.
6. Severe Clostridium difficile-assocaited disease in populations previously at low risk - four states. Centers for Disease Control and Prevention, 2005.
7. Khanna S, Pardi DS, Aronson SL, Kammer PP, Baddour LM. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther 2012; 35: 613–8.
8. Prevention CfDCa. CDC Vital Signs: stopping C difficile infections. 2012 [cited January 6, 2016]. Available from: http://www.cdc.gov/VitalSigns/Hai/StoppingCdifficile.
9. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 28: 1219–27.
10. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55(Suppl. 2): S88–92.
11. Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci 2007; 37: 241–7.
12. Moshkowitz M, Ben-Baruch E, Kline Z, Shimoni Z, Niven M, Konikoff F. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis 2007; 9: 173–7.
13. Shakov R, Salazar RS, Kagunye SK, Baddoura WJ, DeBari VA. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control 2011; 39: 194–8.
14. Bishara J, Farah R, Mograbi J, et al. Obesity as a risk factor for Clostridium difficile infection. Clin Infect Dis 2013; 57: 489–93.
15. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478–98; quiz 99.
16. Multidrug-resistant organism & Clostridium difficile Infection (MDRO/CDI) Module Protocol. Centers for Disease Control and Prevention, 2016.
17. Abou Chakra CN, McGeer A, Labbe AC, et al. Factors associated with complications of Clostridium difficile infection in a multicenter prospective cohort. Clin Infect Dis 2015; 61: 1781–8.
18. Rao K, Micic D, Natarajan M, et al. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis 2015; 61: 233–41.
19. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101–14.
20. Hopkins MJ, Macfarlane GT. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 2002; 51: 448–54.
21. Manges AR, Labbe A, Loo VG, et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis 2010; 202: 1877–84.
22. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022–3.
23. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027–31.
24. Furet JP, Kong LC, Tap J, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010; 59: 3049–57.
25. Abdallah Ismail N, Ragab SH, Abd Elbaky A, Shoeib AR, Alhosary Y, Fekry D. Frequency of Firmicutes and Bacteroidetes in gut microbiota in obese and normal weight Egyptian children and adults. Arch Med Sci 2011; 7: 501–7.
26. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol 2014; 220: T47–59.
27. John BJ, Irukulla S, Abulafi AM, Kumar D, Mendall MA. Systematic review: adipose tissue, obesity and gastrointestinal diseases. Aliment Pharmacol Ther 2006; 23: 1511–23.
28. Mykoniatis A, Anton PM, Wlk M, et al. Leptin mediates Clostridium difficile toxin A-induced enteritis in mice. Gastroenterology 2003; 124: 683–91.
29. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341: 1906–12.
30. Jung KS, Park JJ, Chon YE, et al. Risk factors for treatment failure and recurrence after metronidazole treatment for Clostridium difficile-associated diarrhea. Gut Liv 2010; 4: 332–7.
31. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 2010; 5: e9085.
32. Wu X, Ma C, Han L, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 2010; 61: 69–78.
33. Motzkus-Feagans CA, Pakyz A, Polk R, Gambassi G, Lapane KL. Statin use and the risk of Clostridium difficile in academic medical centres. Gut 2012; 61: 1538–42.
34. Park SW, Choi AR, Lee HJ, et al. The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther 2013; 38: 619–27.
35. Dorner TE, Schwarz F, Kranz A, Freidl W, Rieder A, Gisinger C. Body mass index and the risk of infections in institutionalised geriatric patients. Br J Nutr 2010; 103: 1830–5.
36. Pessaux P, Msika S, Atalla D, Hay JM, Flamant Y; French Association for Surgical R. Risk factors for postoperative infectious complications in noncolorectal abdominal surgery: a multivariate analysis based on a prospective multicenter study of 4718 patients. Arch Surg 2003; 138: 314–24.
37. Via M. The malnutrition of obesity: micronutrient deficiencies that promote diabetes. ISRN Endocrinol 2012; 2012: 103472.